Post by Halozyme, Inc.

We are proud to see Halozyme’s growth story highlighted in this week’s San Diego Business Journal. The SDBJ published a great piece capturing the incredible momentum behind our ENHANZE® drug delivery technology and the strength of our business heading into 2026. A couple of standout points from the article: - Halozyme is projected to exceed $1B in royalty revenue in 2026 – a full year ahead of prior expectations - Strategic acquisitions like Elektrofi and Surf Bio broaden our portfolio of subcutaneous drug delivery technologies and support expected revenue durability As CEO and President Dr. Helen Torley shared, “The interest and progress and performance of ENHANZE has never been stronger.” This is an exciting time for Halozyme as we continue to innovate, grow, and deliver meaningful impact for patients worldwide. Read the full story here: https://lnkd.in/gdy6KAHd #Halozyme #ENHANZE #DrugDelivery #Biotech #Innovation #LifeSciences #Growth